Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Objective To compare the benefits and harms of drug treatments for adults with type 2
diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) …

Insulin resistance (IR) and cardiovascular disease (CVD) represent two universal public
health hazards, especially in today's Western societies. A causal-effect relationship has …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly
improved clinical effects on glycemic control. However, real-world data concerning the …

Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2
inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims …

(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and
cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial …

Background: Randomized controlled trials established the cardiac protection of sodium–
glucose cotransporter-2 (SGLT2) inhibitors among adults with type 2 diabetes. New …

Diabetes mellitus (DM) is a major risk factor for new-onset heart failure (HF) and vice versa.
The pathogenesis of new-onset HF in DM is complex and has been largely attributed to the …

Background GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have
shown to reduce the risk of major adverse cardiovascular events (MACE), death and …

Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …